ARS Pharmaceuticals, Inc. SPRY 深 沪
等待开盘 06-26 09:30:00 美东时间
8.015
-2.525
-23.96%
华盛通- 最 高10.87
- 今 开7.71
- 成交量 768.79万股
- 最 低 7.51
- 昨 收 10.54
- 总市值 0
- 52周最高 18.63
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 6.66
- 委 比 -8.42%
- 总股本 --
- 历史最高 63.41
- 量 比 5.36
- 振 幅 31.88%
- 历史最低 0.00
- 每 手 1
- 风险率 3.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH) stock moved
06-25 20:05
ARS Pharmaceuticals Appoints Donn Casale President, Effective June 1
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced
05-13 20:02
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.
03-26 22:04
ARS Pharmaceuticals: Q4 Earnings Insights
ARS Pharmaceuticals (NASDAQ:SPRY) reported its Q4 earnings results on Monday, M...
03-09 19:36
Earnings Scheduled For March 9, 2026
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is exp...
03-09 19:11
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.
01-10 00:28
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
ARS Pharmaceuticals Launches Get Neffy On Us Commercial Program
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to
2025-11-04 21:04
